Genetic Signatures Stock

Genetic Signatures EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Genetic Signatures (GSS.AX) as of Jul 20, 2026 is -2.03. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.47 — a change of 37.40% (lower).

EV/EBIT

-2.03

YoY

37.40%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Genetic Signatures is 2026 -2.03 . EV/EBIT (Enterprise Value to EBIT) of Genetic Signatures was 2025 -1.47 . It decreases by 37.40% lower compared to the previous year.

The Genetic Signatures EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-29.88 base
Jan 1, 2020
-129.80 base
Jan 1, 2021
139.96 base
Jan 1, 2022
40.32 base
Jan 1, 2023
-4.59 base
Jan 1, 2024
-5.88 base
Jan 1, 2025
-4.39 base
Jan 1, 2026 (e)
-0.89 base
YEARPRICE-TO-EBIT
2026 est -0.89
2025 -4.39
2024 -5.88
2023 -4.59
2022 40.32
2021 139.96
2020 -129.80
2019 -29.88
2018 -24.89
2017 -11.38
2016 -10.54
2015 -21.23
2014 -
2013 -
2012 -
Access this data via the Eulerpool API
Get Free API Key

Genetic Signatures Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Genetic Signatures's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Genetic Signatures's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Genetic Signatures's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Genetic Signatures grows earnings faster than its peers.

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

EV/EBIT (Enterprise Value to EBIT) of Genetic Signatures is -2.03 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Genetic Signatures

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Genetic Signatures